»Ê¼Ò»ªÈË

The Epilepsy12 audit supports continuous improvement activities within paediatric epilepsy services in England and Wales. We aim to improve clinical outcomes and reduce variation in care quality for children and young people with epilepsy.

This report provides an overview from the self-assessments completed by paediatric diabetes units in England and Wales between 2018 and 2022. More than 150 self-assessment measures evaluate compliance to the programme and to Best Practice Tariff requirements.

This report highlights the impact our programme had on paediatric diabetes units across England and Wales from 2018 to early 2023, from the successful Quality Improvement Collaboratives to individual service peer reviews and self-assessment.

This statement is produced by Neonatal and Paediatric Pharmacy Group (NPPG), with support from RCPCH. There are no licensed oral liquid calcium or phosphate products available in the UK. Administration of an effervescent calcium or phosphate tablet is common, and this statement provides guidance for...

RCPCH &Us speaks to children and young people (CYP) throughout the UK to share their views and experiences of health and healthcare. These views have been collated to create a ‘Voice Bank’ containing a rich source of information on CYP ideas, concerns and expectations which is vital knowledge for he...

There are a number of governance systems in place to ensure the smooth delivery of the Epilepsy12 audit. Further information can be found below.